NCT03700138View on ClinicalTrials.gov

Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

April 10, 2025

Study Completion Date

April 10, 2025

Conditions
Primary Sjögren's Syndrome Painful Sensory Neuropathies
Interventions
DRUG

Privigen® 100mg/ml at the dose of 2g/kg of body weight

The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).

DRUG

NaCl 0,9%

The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).

Trial Locations (1)

67000

University Hospital, Strasbourg, france, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER

NCT03700138 - Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies | Biotech Hunter | Biotech Hunter